PTHS Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-22.920.0% YoY
Profit margin-186.2%HEALTHCARE
Market cap$100.8MMicro cap
Wall Street coverage
$57.71median target· current $15.50 (+272.3%)7 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 2.67
- P/S (TTM)
- 3.42
- EV/EBITDA
- -3.58
Profitability & growth
- ROE (TTM)
- -333.8%
- Operating margin
- -120.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 3.20
Last earnings
May 14, 2026 · Estimate $-3.58 · Reported $-4.66
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
33 articles · sorted by datePage 1 of 2 · 33 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Pelthos Therapeutics Inc.
Company profilePelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company is headquartered in Durham, North Carolina.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- AMEX
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 4020 STIRRUP CREEK DRIVE, DURHAM, NC
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$100.8M
Shares outstanding$3.5M
52W high$37.50
52W low$11.20
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent